1. Introduction {#sec1}
===============

Allergy is one of the most prevalent diseases worldwide. More than half (54.6%) of all US citizens test positive to ≥1 allergen [@bib1], and 300 million people worldwide have asthma, with 250,000 annual deaths attributed to the disease [@bib2]. As a therapeutic agent against allergy, histamine-fixed immunoglobulin (Ig) preparation has been used for bronchial asthma, allergic rhinitis, and atopic dermatitis [@bib3; @bib4; @bib5; @bib6].

The histamine-fixed Ig preparation Histobulin™ (Green Cross PD, Korea) comprises 0.15 μg of histamine dihydrochloride and 12 mg of IgG. Histobulin was developed from histamine-fixed serum that was able to inhibit antigen-induced histamine release from human peripheral blood basophils and rat peritoneal mast cells [@bib7; @bib8]. Some scholars assumed that the histamine from the Ig induces antihistamine antibody, so as to provide resistance after allergen challenge [@bib3].

However, excessive administration of histamine may cause hypotension or hypertension, headaches, or anaphylactic shock syndrome [@bib9]. Therefore the histamine content in the pharmaceutical should be controlled by regulation. Since the Ig of Histobulin is derived from human blood plasma, it is regulated by national authority as a biological that should pass the lot-release test before marketing [@bib10]. Therefore development of a validated quantitative method for the quantification of histamine in Histobulin is very important for quality control of the drug to increase safety. Besides the safety aspect, Histobulin does not have a potency test; therefore, histamine quantification can also serve as potency test related to the efficacy of the drug.

Analysis of histamine is mainly based on chromatographic methods such as thin-layer chromatography (TLC), capillary electrophoresis (CE), and high-performance liquid chromatography (HPLC) [@bib11]. The current method for histamine detection of preparations in lot-release test (specification: histamine should be \<0.5 μg/12 mg Ig) uses o-phthaldehyde (OPA)-derivatized histamine detection by fluorimetric method or TLC after serial solvent extraction of Histobulin. However, these analyses have low accuracy and specificity. Therefore HPLC methods have mainly been used for histamine quantification, because they provide good specificity and sensitivity when coupled with a highly sensitive detector. Whereas histamine does not have UV-visible absorbance in its chemical structure, derivatization with fluorogenic reagents is the popular way to detect it by fluorescence detector with HPLC, which can improve the detection limit compared with the current test methods for the national lot-release test mentioned above. Therefore the majority of histamine assays employ fluorometric detection with pre- or post-column derivatization [@bib12; @bib13] using dansyl chloride [@bib13; @bib14], fluorescamine [@bib14], and OPA as labeling agents [@bib15; @bib16; @bib17].

Recently, a new analytical method including separation of histamine from pharmaceutical matrices using a polystyrene-divinylbenzene (PS-DVB) polymer and subsequent pre-column derivatization with OPA prior to HPLC analysis was reported [@bib18]. However, OPA derivatization of the preparation may not have enough stability to adjust national lot-release test [@bib19]. Therefore the aim of this study was to develop an HPLC method using the novel fluorescent derivatizing agent 2,3-naphthalenedicarboxaldehyde (NDA) and to optimize the analytical conditions, including extraction column selection and steps to improve sensitivity and reproducibility compared with OPA-derivatized histamine HPLC analysis. In addition, this study compared the current lot-release test methods, TLC and fluorimetry, with the new HPLC method for application to the national lot-release test. The HPLC method was also validated following FDA guidelines for validation of analytical assays [@bib20].

2. Materials and Methods {#sec2}
========================

2.1. Materials and reagents {#sec2.1}
---------------------------

Histamine dihydrochloride (2-\[4-imidazole\]ethylamine · dihydrochloride, C~5~H~9~N~3~ · 2HCl; FW, 184.1), 2-mercaptoethanol, 3-methyl-histamine dihydrochloride (C~6~H~11~N~3~2H Cl; FW, 198.1), sodium hydroxide, OPA (C~8~H~6~O~2~; FW, 134.13), and NDA (C~12~H~8~O~2~; FW, 184.2) were purchased from Sigma-Aldrich Co. (St. Louis, MO, USA). HPLC-grade acetonitrile and methanol were supplied by Fisher Scientific (Fair Lawn, NJ, USA). The reagents used for HPLC mobile phase were used as HPLC grade. All chemicals and reagents of analytical grade were used without further purification. Deionized water (DIW) was obtained from a Milli-Q water purification system (Millipore, Bedford, MA, USA). The Ig pharmaceutical (Histobulin™), human gamma-Ig with histamine and matrix compositions, was provided by Green-Cross PD Co. (Oh Chang, Chung Buk Province, Korea). One vial of Histobulin™ comprises 12 mg of lyophilized human IgG (hIgG) and 0.15 μg of histamine. Other ingredients include sodium chloride (isotonic agent, 4 mg), glycine (stabilizer, 45 mg), D-mannitol (builder, 4 mg), and sodium hydroxide (pH adjuster, trace amount). The blank matrix included the same composition with the pharmaceutical except histamine. Two reverse-phase solid-phase extraction (SPE) cartridges with styrenedivinylbenzene (SDB)-coated resin, Strata SDB-L (500 mg; particle size, 83 μm; pore size, 260Å, surface area, 500 m^2^/g), Strata SDB-X (500 mg; particle size, 33 μm; pore size, 85Å; surface area, 800 m^2^/g), and one cation exchange SPE cartridge, Strata SDB-X-CW (500 mg; 3 mL; particle size, 33 μm; pore size, 85Å; surface area, 800 m^2^/g) were purchased from Phenomenex Co. (Torrance, CA, USA).

2.2. Instruments and apparatus {#sec2.2}
------------------------------

The HPLC system was the Waters 2695 separation module equipped with a Waters 2475 multi-λ fluorescence detector (Milford, MA, USA) and a CH-150 column oven (Eldex Lab, CA, USA). Injected samples were separated on a Luna^®^phenylhexyl analytical column (5 mm; 103 A 250 × 4.6 mm i.d.; Phenomenex) preceded by a phenyl guard column (3.0 × 4.0 mm i.d.; Phenomenex). The HPLC software was DsChrom (ver. 2000 Net, Donam Inst., Seoul, Korea). Shimadzu RF-1501 spectro-fluoro-photometer (Tokyo, Japan) or Perkin Elmer LS 45 fluorescence spectroscopy (Perkin Elmer, Waltham, MA, USA) was used for fluorimetry.

2.3. Standards preparation {#sec2.3}
--------------------------

Histobulin™ was reconstituted with 1 mL of water for injection (WFI) per vial then were added 150 μL of 3-methylhistamine · 2HCl, internal standard (IS; 1 μg/mL), and 170 μL of 1 N sodium hydroxide to adjust to pH 9.5 followed by adding DIW to make final volume 2 mL. Histamine · 2HCl was diluted to 0, 25, 50, 75, 100, and 150 ng/mL with 100 mM sodium acetate, pH 9.5, containing 150 ng of 3-methylhistamine · 2HCl as IS.

2.4. Solid-phase extraction and sample preparation {#sec2.4}
--------------------------------------------------

Three SPE cartridges were washed with 2 mL methanol three times followed by three times of 2 mL DIW rinsing. Each concentration of standards or sample solution was loaded to rinsed SPEs by gravity. The vials of standard or sample were rinsed with 1 mL of DIW then loaded to the cartridges to bed volume (1.2 mL). The columns were washed with 2 mL of DIW three times followed by 1 mL of 40% (v/v) methanol in DIW washing three times. Then, the cartridges were eluted with 2 or 5 mL of 100 mM sodium acetate, pH 9.5, and methanol (20% v/v). The histamine-containing eluent was used for derivatization reaction.

2.5. Derivatization reaction {#sec2.5}
----------------------------

For NDA-fluorescent labeling, 0.6 mL of extract of standard or sample was mixed with 0.2 mL borate buffer, pH 9.5, with 10% (v/v) acetonitrile, then 0.2 mL of 20 mM sodium cyanide solution was added and the mixture vortexed for 1 minute. The mixture reacted with 0.4 mL of NDA (0.3 mM in methanol) at room temperature for 4 hours because of relatively slow reaction [@bib19; @bib21] ([Scheme 1](#sch1){ref-type="fig"}). After the reaction, 50 μL of aliquots were injected into the HPLC system. For OPA-derivatization of histamine in the extracts, 20 mg of OPA was dissolved in 1 mL ethanol and 20 μL of 2-mercaptoethanol was added to the solution. Then, 100 mM borate buffer, pH 9.5, was added to the OPA-containing solution to make a final volume of 20 mL (OPA solution). OPA solution of 0.4 mL was added to 1.6 mL of standard or sample extracts and mixed vigorously for 30 seconds [@bib18].

2.6. HPLC analysis {#sec2.6}
------------------

HPLC separation was performed on a reversed-phase phenyl-hexyl column (4.6 × 250 mm; particle size, 5 μm; Phenomenex) kept at 40°C using a mobile phase consisting of acetonitrile--phosphate buffer (pH 6.8; 50 mM) (35:65 v/v) at flow rate 1 mL/minute for OPA and 2 mL/minute for NDA with 50 μL sample injection. Fluorescence detection was achieved for OPA and NDA at excitation maximum of 340 and 424 nm and emission maximum 450 and 484 nm, respectively. The chromatogram peak area of histamine from standard and samples to the area of internal standard was calculated to determine histamine content.

2.7. Fluorimetry analysis {#sec2.7}
-------------------------

Fluorimetry followed a modified method of Glick et al [@bib22]. Briefly, histamine standard solution (15 μg/mL in DIW) was diluted to 0, 0.15, 0.3, and 0.6 μg/mL with DIW. Three vials of Histobulin™ were reconstituted with 1 mL DIW, then pooled (total volume, 3 mL). After serial extraction steps with organic solvents, 2.5 mL of water layer in the bottom of the solution was collected then were added 0.14 mL 4 N hydroxide and 0.1 mL OPA (1 mg/mL in methanol) and reacted in the dark for 5 minutes. To stop the reaction 0.28 mL of 42% citric acid was added. The reactant was read by fluorescence spectroscopy at 360 nm excitation maximum and 450 nm emission maximum to determine histamine concentration in the sample from the standard dose--response curve.

3. Results and Discussion {#sec3}
=========================

3.1. Sample cleanup by various SPE cartridges {#sec3.1}
---------------------------------------------

The biggest difficulty encountered for histamine analysis of pharmaceuticals is the complexity of the real drug matrix and the quite low amounts of histamine to be monitored. In Histobulin, glycine is used as stabilizer, which has an amine in the molecule that can react with fluorescent materials, causing low reproducibility in the analysis. Therefore pre-column derivatization can be an effective solution not only to remove the matrix signal, but also to determine submicro amounts of histamine in the drug that affect the fluorogenic labeling reaction. Accordingly, separation of the submicro amounts of histamine (0.15 μg) from the main components, glycine (45 mg) and Ig (12 mg), which can also react with fluorogenic reagents, is critical in terms of adequate recovery prior to HPLC analysis.

Although many cleanup procedures can be used for isolation of biogenic amines from samples with complex matrices, the C18-bonded silica SPE cartridge has been widely used for trace enrichment of nonpolar and moderately polar solutes. Recently, Kim et al. [@bib18] reported that SDB-L SPE was simple to use, stable in alkaline pH, and effective to separate organic compounds from hydrophilic samples; sample pH 9--10 was optimal in extraction yield (\>90%). In this study, we used three types of SPE to increase recovery and decrease other matrices in the eluent, including glycine, which can be conjugated with fluorescent signal generator in the next step. SDB-L showed 73.7% recovery of histamine and 74.0% of 3-methyl-histamine as an internal standard, which was similar to a previous study [@bib18]. Comparable results were observed when the polymeric sorbent surface-modified SDB-X extraction was used. The recovery of SDB-X to histamine and 3-methyl-histamin was determined as 74.4% and 85.9%, respectively. However, polymeric sorbent surface-modified SDB-X-CW did not show good recovery yield (data not shown). Although polymeric sorbent SDB-L and SDB-X showed similar recovery, SDB-L had a shorter extraction time. Therefore we determined that SDB-L was optimal for the separation. From the results, it was concluded that histamine interacted strongly with SDB-L sorbent and SDB-X even if they existed in free base or singly charged form between pH 9--10 according to its pK values. To increase sensitivity of histamine in HPLC analysis, the concentration of eluent was optimized. The elution volume at the histamine recovery stage was reduced from 5 to 2 mL, which was used in a previous study [@bib18]. Comparing HPLC analyses of the extracted samples with elution volume of 2 and 5 mL, the 2-mL eluent showed more than twice the increase in sensitivity of histamine and IS in a chromatogram with OPA as the labeling agent ([Table 1](#tbl1){ref-type="table"}, [Figure 1](#fig1){ref-type="fig"}). Additional washing solution after 2 mL elution did not show any histamine peak in the chromatogram of HPLC, suggesting that our system maintained histamine recovery even though the elution volume was reduced to a minimum. Most of the Ig of large molecular size washed out during the initial washing step. Meanwhile, histamine was strongly retained in the SPE sorbent phase during the washing steps, whereas almost all histamine was eluted in small volumes (approximately 2 mL) of eluent.

3.2. Comparison of fluorescent labeling agents OPA with NDA in histamine derivatization {#sec3.2}
---------------------------------------------------------------------------------------

Histamine and OPA reacted faster than NDA in the presence of 2-mercaptoethanol as co-ligand [@bib18]. However, the stability of OPA is questionable, which might affect reproducibility of the assay [@bib19; @bib23]. Therefore we selected NDA as an alternative fluorescent agent; NDA produced an improved chromatogram with stable baseline and retention time within the target in our system ([Figure 2](#fig2){ref-type="fig"}), but longer reaction time was needed because of the relatively slow chemical reaction [@bib19]. However, the longer reaction time (4 hours at room temperature) did not affect any factors in point-of-method validation, such as specificity, accuracy, and precision. The chromatogram baseline around the histamine peak, which might affect sensitivity of the analysis, was stabilized when NDA was used as a fluorescent labeling agent because of reduced byproducts formation, whereas OPA gave some byproduct peaks around the histamine peak and relatively unstable baselines during 6 samples analyses period, because of instability of OPA ([Figure 2](#fig2){ref-type="fig"}). These findings made us decide that NDA was the optimal fluorescent agent in this derivatization step.

3.3. HPLC analysis {#sec3.3}
------------------

Due to the optimization of eluent concentration in the extraction step, the detection limit of histamine was lowered to 7.58 ng/mL using NDA-labeled samples on reversed-phase HPLC with isocratic elution of the mobile phase of acetonitrile--phosphate buffer (pH 6.8; 50 mM) (35:65 v/v). In the preliminary study, we compared methanol versus acetonitrile as the mobile phase with a 0.5--2 mL/minute flow rate. However, methanol and the slower flow rate gave lower sensitivity and an inapplicable detection limit (data not shown) when NDA was utilized as a fluorescent derivatizer. Therefore 35% acetonitrile with 2 mL/minute was decided to be optimal. The mean retention time of histamine was 8.80 ± 0.1 minutes for OPA-labeled histamine and 11.80 ± 0.001 minutes for NDA-labeled histamine. IS retention time for OPA-- and NDA-labeled IS was 11.07 ± 0.1 and 16.70 ± 0.001 minutes, respectively, which also showed complete baseline separation with histamine in both fluorescents ([Figure 2](#fig2){ref-type="fig"}). The HPLC retention time of OPA-labeled histamine and IS was similar to that in the previous report [@bib18].

3.4. Validation of HPLC analysis {#sec3.4}
--------------------------------

Using this optimized NDA-derivatized histamine analysis method, validation tests were performed with histamine-spiked matrix solution, including accuracy, precision, linearity, specificity, and detection limit,. The accuracy test used histamine (0.025, 0.05, 0.075, 0.10, and 0.15 μg/mL)-spiked matrix solution with 0.15 μg/mL IS. Recovery was 90--105% at each concentration; relative standard deviation (RSD) was \<4.0% ([Tables 2 and 3](#tbl2 tbl3){ref-type="table"}) and R^2^ of the dose--response curve was \>0.992 ([Table 4](#tbl4){ref-type="table"}), which was comparable to the control solution with the same range of histamine-added matrix solution (R^2^ = 0.992; *n* = 3). The histamine concentration of Histobulin™ is 0.075 μg/mL. Therefore histamine in the pharmaceutical can be quantitatively determined by this dose--response curve. Day-to-day analysis for 3 days (*n* = 6 per day) showed good intraday and interday precision (RSD \<2%) ([Table 3](#tbl3){ref-type="table"}). Therefore the accuracy, linearity, and repeatability of the analysis were validated. Using 0.075 μg/mL of IS only and histamine standard-spiked solution revealed baseline separated peaks in HPLC, suggesting that this system had good specificity. Based on the above reproducibility assessment data, detection limit and range was determined. The equation (10 × б)/S was used for quantization limit and (3.3 × б)/S for detection limit, where б is the standard deviation of intercept and S the average of the slope of the dose--response curve based on accuracy test. Quantitative limit and detection limit were determined as 0.0229 and 0.0076 μg/mL, respectively; both were in the targeted range 0.025--0.15 μg/mL. This dose--response curve can be used for quantification of histamine in pharmaceuticals.

3.5. Comparison of histamine content test from Histobulin™ for lot-release test {#sec3.5}
-------------------------------------------------------------------------------

Current lot-release test methods for Histobulin, TLC and fluorimetry were compared with HPLC analysis of histamine from Histobulin using NDA as the fluorescent agent. With 15 lots of Histobulin™ as samples, an average of 0.17 ± 0.016 μg/12 mg Ig per vial (range, 0.15--0.21 μg/vial) was determined by HPLC analysis. Meanwhile the fluorimetry method produced a result of 0.025 ± 0.013 μg/vial (range, 0.0045--0.0454 μg/vial; [Figure 3](#fig3){ref-type="fig"}). The TLC method only provided a qualitative analysis. The amount of histamine in the pharmaceutical satisfied the current specification (\<0.5 μg/vial) in both analyses. However, that from the new HPLC method resulted in a slightly higher than expected amount (0.15 μg/vial). Therefore we plan to investigate the reason for this with the manufacturer of Histobulin as a further study, to set new specifications for histamine in this pharmaceutical.

3.6. Conclusion {#sec3.6}
---------------

The histamine quantification method using HPLC after pre-column extracted Ig preparation with NDA derivatization was optimized and validated. NDA utilized HPLC method for histamine quantification in the preparation may compensate current test method for histamine detection which has complicate extract steps resulting inaccurate results frequently. This method will soon be applied to the national lot-release test and the specification of histamine content in pharmaceuticals including histamine-added hIg will be set with the accumulated lot-release test based on standard deviation ranges ([Figure 4](#fig4){ref-type="fig"}).
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![Representative chromatograms of HPLC with OPA-labeled histamine. (A) Standard solutions of histamine and 3-methyl histamine (IS). (B) Histamine-added pharmaceuticals extracted by SDB-L SPE and (C) by SDB-X SPE.](gr1){#fig1}

![HPLC chromatograms of different fluorescent labeling agents: (A) OPA; and (B) NDA. Six different concentrations of histamine-containing samples with IS were analyzed and the chromatograms overlapped after each fluorescent agents' derivatization.](gr2){#fig2}

![Comparison of analytic methods of histamine using 15 lots of histamine-added human immunoglobulin: current lot-release test method using fluorometry (red squares) and new HPLC method (blue diamonds) are shown. For HPLC method, *n* = 3; Bars, SD.](gr3){#fig3}

![Trend analysis of histamine content in 15 lots of human immunoglobulin preparations with histamine. Mean ± SD was 0.168 ± 0.016 μg/vial. 2SD and 4SD lines are shown as dotted lines.](gr4){#fig4}

![Derivatization reaction schemes of OPA (A) and NDA (B) with histamine.](sc1){#sch1}

###### 

Effect of reduced extraction volume in SPE cartridge on HPLC analysis of histamine and internal standard in human immunoglobulin spiked with 0025 μg of histamine (*n* = 6)

  Extraction volume   Recovery (%)     Histamine area   IS area
  ------------------- ---------------- ---------------- --------------
  2 mL                111.72--112.92   19.12--20.16     29.63--30.88
  5 mL                108.63--115.92   9.69--10.60      14.45--14.54

###### 

Recovery of histamine in matrix samples prepared by spiking different concentrations of histamine with 0.075 μg/mL of IS

  Spiked amount (μg)   Final conc. (μg/mL)   HPLC analysis result (μg/mL)   RSD (%)   Recovery (%)
  -------------------- --------------------- ------------------------------ --------- --------------
  0.05                 0.025                 0.0258 ± 0.0008                3.27      103.2
  0.10                 0.050                 0.0490 ± 0.0019                3.85      97.9
  0.15                 0.075                 0.0713 ± 0.0024                3.34      95.0
  0.20                 0.100                 0.0916 ± 0.0017                1.89      91.6
  0.30                 0.150                 0.1525 ± 0.0014                0.94      101.7

Mean ± SD (*n* = 6).

RSD = relative standard deviation.

###### 

Intra-day and inter-day analyses of HPLC using NDA-labeled histamine in matrix sample prepared by spiking histamine with 0.075 μg/mL of IS

  Histamine spiked (μg)   Histamine concentration (μg/mL)   Day   Histamine conc. (μg/mL)   RSD (%)   Recovery (%)
  ----------------------- --------------------------------- ----- ------------------------- --------- --------------
  0.15                    0.075                             1     0.0747 ± 0.0004           0.51      99.59
  0.15                    0.075                             2     0.0777 ± 0.0004           0.56      103.61
  0.15                    0.075                             3     0.0784 ± 0.0011           1.40      104.47

Mean ± SD (*n* = 6).

RSD = relative standard deviation.

###### 

Linearity of dose--response curves of HPLC analysis for NDA-labeled histamine on days 1--3

  HPLC analysis   R^2^              Dose response curve parameters   
  --------------- ----------------- -------------------------------- ------------------
  Day 1           0.9950            0.0245                           −0.1880
  Day 2           0.9916            0.0243                           −0.1930
  Day 3           0.9928            0.0277                           −0.0892
  Mean ± SD       0.9931 ± 0.0017   0.0255 ± 0.0019                  −0.1567 ± 0.0585

SD = standard deviation.
